Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
Status:
Completed
Trial end date:
1993-07-01
Target enrollment:
Participant gender:
Summary
This study will determine the effectiveness of desipramine in improving cellular signaling,
and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
Phase:
Phase 4
Details
Lead Sponsor:
Harvard Medical School Harvard Medical School (HMS and HSDM)